Voronoi, Inc

310210 · KOSDAQ

Public Market Listing

310210KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for Voronoi, Inc are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1/2
EGFR/HER2Small molecule
Non-Small Cell Lung Cancer
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
EnozertinibPhase 1/2Solid Tumors
Est. primary completion 2027-06 · NCT05315700 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
VRN110755Phase 1/2EGFR-Mutant Non-Small Cell Lung Cancer
Est. primary completion 2029-01-01 · NCT07699328 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.